RSPO2-Based Peptibodies Conjugated with Pyrrolobenzodiazepine Dimer or Camptothecin Analogs Demonstrate Potent Antitumor Activity by Targeting the Three Receptors LGR4/5/6 in Colorectal Cancer and Neuroblastoma
- 9 April 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (8) , 9302-9313
Abstract
Leucine-rich repeat-containing, G protein-coupled receptors 4, 5, and 6 (LGR4/5/6) are coexpressed or alternately expressed at high levels in tumor cells of colorectal cancer (CRC) and high-risk neuroblastoma (NB). Simultaneous targeting of all three homologous receptors may improve efficacy or overcome drug resistance due to tumor heterogeneity and cancer cell plasticity. R-spondins (RSPOs) bind to LGR4/5/6 with a high affinity and potentiate Wnt/β-catenin signaling. We previously reported that a mutant RSPO4 furin domain-based peptibody that binds to LGR4/5/6 without potentiating Wnt/β-catenin signaling was able to deliver cytotoxins into cancer cells that express any of the three receptors. Here, we generated a mutant RSPO2 furin domain that retains high-affinity LGR4/5/6 binding without any signaling activity. RSPO2 furin mutant peptibodies conjugated with pyrrolobenzodiazepine dimer (PBD) or camptothecin derivative (CPT2) yielded potent, target-selective cytotoxicity in LGR4/5/6-positive CRC and high-risk NB cell lines in vitro and robust antitumor activity in vivo.Keywords
Funding Information
- National Cancer Institute (R21CA267381)
- National Cancer Institute (R41CA281553)
- DOD Peer Reviewed Cancer Research Program (CA230331)
- Cancer Prevention and Research Institute of Texas (RP210119)
- Cancer Prevention and Research Institute of Texas (RP220169)
- Cancer Prevention and Research Institute of Texas (RP220480)
- Janice David Gordon for Bowel Cancer Research Endowment
- Center for NextGen Therapeutics, Baylor College of Medicine
This publication has 55 references indexed in Scilit:
- Evaluation of Double Self-Immolative Linker-Based Antibody–Drug Conjugate FDA022-BB05 with Enhanced Therapeutic PotentialJournal of Medicinal Chemistry, 2024
- Development of Asialoglycoprotein-Mediated Hepatocyte-Targeting Antitumor Prodrugs Triggered by GlutathioneJournal of Medicinal Chemistry, 2021
- Drug Conjugates of Antagonistic R-Spondin 4 Mutant for Simultaneous Targeting of Leucine-Rich Repeat-Containing G Protein-Coupled Receptors 4/5/6 for Cancer TreatmentJournal of Medicinal Chemistry, 2021
- Antibody-drug conjugates as targeted therapies: Are we there yet? A critical review of the current clinical landscapeDrug Discovery Today: Technologies, 2020
- Crystal structure of R-spondin 2 in complex with the ectodomains of its receptors LGR5 and ZNRF3Journal of Structural Biology, 2015
- A nineteen gene‐based risk score classifier predicts prognosis of colorectal cancer patientsMolecular Oncology, 2014
- Children's Oncology Group's 2013 blueprint for research: NeuroblastomaPediatric Blood & Cancer, 2012
- Monoclonal Antibodies Against Lgr5 Identify Human Colorectal Cancer Stem CellsStem Cells, 2012
- LGR5‐Positive Colon Cancer Stem Cells Interconvert with Drug‐Resistant LGR5‐Negative cells and are Capable of Tumor ReconstitutionStem Cells, 2012
- Identification and Cloning of an Orphan G Protein-Coupled Receptor of the Glycoprotein Hormone Receptor SubfamilyBiochemical and Biophysical Research Communications, 1998